Item 7.01 Regulation FD Disclosure.
Aquestive Therapeutics, Inc. (the “Company”) is furnishing this Current Report
on Form 8-K in connection with the disclosure of information, in the form of an
investor presentation to be given at meetings with institutional investors,
analysts and others. This information may be amended or updated at any time and
from time to time through another Current Report on Form 8-K, a later company
filing or other means. A copy of the Company’s investor presentation is attached
hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into
this Item 7.01 by reference. The investor presentation is available on the
Company’s website located at http://www.aquestive.com, although the Company reserves
the right to discontinue that availability at any time.
The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed
to be “filed” for purposes of, or otherwise subject to the liabilities of,
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), nor shall it be deemed to be incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in any such filing.
Item 8.01 Other Events.
On June 15, 2022, the Company issued a press release providing a business update
in connection with the positive topline data from the first three arms of Part 3
of the EPIPHAST study for the Company’s AQST-109 epinephrine oral film product
candidate in clinical development. A copy of the Company’s press release is
attached hereto as Exhibit 99.2 and incorporated into this Item 8.01 by
Item 9.01 Financial Statements and Exhibits. (d)Exhibits. Exhibit Description Number 99.1 Investor Presentation 99.2 Press Release dated June 15, 2022.
© Edgar Online, source Glimpses